Lee Greenberger Discusses Blood Cancer Research and the Leukemia and Lymphoma Society

Article

Lee Greenberger, PhD, chief scientific officer, The Leukemia & Lymphoma Society, discusses how the society contributes to blood cancer research.

Lee Greenberger, PhD, chief scientific officer, The Leukemia & Lymphoma Society, discusses how the society contributes to blood cancer research.

The Leukemia & Lymphoma Society recently passed the $1 billion mark in research investment, Greenberger said. The society currently has 320 active programs available.

The journey from a laboratory discovery to a therapy that can control disease takes about 10 years. Sustained funding is needed in order to make progress in this field, Greenberger says, and the society’s volunteers, advocates, and cancer patients step up in order to make progress in the field happen.

To learn more about The Leukemia & Lymphoma Society, visit www.lls.org.

Related Videos
Related Content
FDA Requires Boxed Warnings for CAR T-Cell Therapies

FDA Requires Boxed Warnings for CAR T-Cell Therapies

April 22nd 2024
Article

All patients treated with CAR T-cell products are recommended to be monitored life-long for the risk of secondary malignancy, according to the FDA.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Tamibarotene-Based Combo Receives Fast Track Designation from the FDA for AML

Tamibarotene-Based Combo Receives Fast Track Designation from the FDA for AML

April 17th 2024
Article

The FDA granted tamibarotene plus azacitidine and venetoclax fast track designation for the treatment of newly diagnosed, unfit, RARA-overexpressed AML.

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

December 1st 2023
Podcast

Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.

Image of "FDA Approved" in blue and green.

Idecabtagene Vicleucel Approved by FDA in R/R Multiple Myeloma

April 5th 2024
Article

The FDA has approved idecabtagene vicleucel for patients with relapsed/refractory multiple myeloma who have received 2 prior lines of therapy.

Frontline Ibrutinib May Be Effective and Well Tolerated in Low-Risk MCL

Frontline Ibrutinib May Be Effective and Well Tolerated in Low-Risk MCL

April 4th 2024
Article

Findings from this study demonstrated effectiveness with frontline ibrutinib in patients with previously treated, low-risk mantle cell lymphoma regardless of whether rituximab was added.

© 2024 MJH Life Sciences

All rights reserved.